SA99200492B1 - طريقة لمنع بداية الربو Asthma - Google Patents

طريقة لمنع بداية الربو Asthma Download PDF

Info

Publication number
SA99200492B1
SA99200492B1 SA99200492A SA99200492A SA99200492B1 SA 99200492 B1 SA99200492 B1 SA 99200492B1 SA 99200492 A SA99200492 A SA 99200492A SA 99200492 A SA99200492 A SA 99200492A SA 99200492 B1 SA99200492 B1 SA 99200492B1
Authority
SA
Saudi Arabia
Prior art keywords
patient
asthma
cetirizine
given
aforementioned
Prior art date
Application number
SA99200492A
Other languages
Arabic (ar)
English (en)
Inventor
لوك يولينبروك
مارك دي لونجويفيل
آن ويلمز
جوهان دي كليرك
Original Assignee
يو سي بي ، اس ايه
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA99200492(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by يو سي بي ، اس ايه filed Critical يو سي بي ، اس ايه
Publication of SA99200492B1 publication Critical patent/SA99200492B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SA99200492A 1998-08-18 1999-08-18 طريقة لمنع بداية الربو Asthma SA99200492B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9692998P 1998-08-18 1998-08-18
US9745598P 1998-08-21 1998-08-21

Publications (1)

Publication Number Publication Date
SA99200492B1 true SA99200492B1 (ar) 2006-06-04

Family

ID=26792214

Family Applications (1)

Application Number Title Priority Date Filing Date
SA99200492A SA99200492B1 (ar) 1998-08-18 1999-08-18 طريقة لمنع بداية الربو Asthma

Country Status (16)

Country Link
EP (1) EP1109557B1 (enExample)
JP (1) JP3878416B2 (enExample)
AR (1) AR020167A1 (enExample)
AT (1) ATE228366T1 (enExample)
AU (1) AU749169B2 (enExample)
CA (1) CA2340920C (enExample)
DE (1) DE69904206T2 (enExample)
ES (1) ES2188232T3 (enExample)
HN (1) HN1999000140A (enExample)
MA (1) MA26676A1 (enExample)
MY (1) MY124089A (enExample)
PA (1) PA8480401A1 (enExample)
SA (1) SA99200492B1 (enExample)
TN (1) TNSN99158A1 (enExample)
TW (1) TW581675B (enExample)
WO (1) WO2000010544A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221854A1 (en) * 2000-12-15 2002-06-24 U C B, S.A. Use of cetirizine or efletirizine for preventing urticaria
WO2005077371A1 (en) * 2004-02-12 2005-08-25 Ucb Farchim Sa Use of levocetirizine for the preparation of a drug
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof

Also Published As

Publication number Publication date
ES2188232T3 (es) 2003-06-16
JP2002523362A (ja) 2002-07-30
EP1109557A2 (en) 2001-06-27
TW581675B (en) 2004-04-01
ATE228366T1 (de) 2002-12-15
EP1109557B1 (en) 2002-11-27
MA26676A1 (fr) 2004-12-20
JP3878416B2 (ja) 2007-02-07
WO2000010544A3 (en) 2000-05-18
DE69904206D1 (de) 2003-01-09
CA2340920C (en) 2007-10-16
DE69904206T2 (de) 2003-07-17
HN1999000140A (es) 2001-07-31
WO2000010544A2 (en) 2000-03-02
PA8480401A1 (es) 2000-09-29
AU749169B2 (en) 2002-06-20
CA2340920A1 (en) 2000-03-02
AR020167A1 (es) 2002-04-10
MY124089A (en) 2006-06-30
TNSN99158A1 (ar) 2005-11-10
AU5734699A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
Wahn Allergic factors associated with the development of asthma and the influence of cetirizine in a double‐blind, randomised, placebo‐controlled trial: First results of ETA®
Meltzer et al. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment
KR20100045457A (ko) 알코올 소비의 증상을 감소시키는 방법
RU2672871C2 (ru) Применение левоцетиризина и монтелукаста при лечении травматических повреждений
Chen et al. Disodium cromoglycate, a new compound for the prevention of exacerbations of asthma
US20230233555A1 (en) Method of administering upadacitinib to avoid adverse drug interactions and effects
Phillpotts et al. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-α2
SA99200492B1 (ar) طريقة لمنع بداية الربو Asthma
Garnham et al. Serum concentrations and bioavailability of rifampicin and isoniazid in combination.
US6432961B1 (en) Method for preventing the onset of asthma
US20230248726A1 (en) Pharmaceutical composition and application thereof
EP1569650B1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
Hayden et al. Topical phenylephrine for the treatment of middle ear effusion
Hung et al. Regulation of stromal cell-derived factor-1 and exhaled nitric oxide in asthmatic children following montelukast and ketotifen treatment
EP4353234A1 (en) Use of pyrrolopyrimidine compound
Conway et al. Slow release theophylline in preschool asthmatics.
JP2024514347A (ja) Ｊａｋ３／ｊａｋ１／ｔｂｋ１選択的阻害剤を含む医薬組成物及びその医薬用途
Tiwari et al. Effectiveness and Possible Side effects of the Covishield Vaccine in Preventing Covid-19
WO2002047689A2 (en) Use of cetirizine or efletirizine for preventing urticaria
KORSANTIA et al. PEMPHIGUS VULGARIS, CURRENT STATUS AND PROSPECTS
Quie et al. Recurrent Staph Infection in Two Generations
Prophylactic Ascorbic Acid for the Common Cold
JP2016535793A (ja) 口腔アレルギー症候群の予防および治療のための製剤および方法
WO2004105760A1 (en) Use of efletirizine for treating persistent allergic rhinitis
US20140213644A1 (en) Formulations and Methods for Prevention and Treatment of Oral Allergy Syndrome